These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 1762471)

  • 1. A computer simulation model for cost-effectiveness analysis of cardiovascular disease prevention.
    Johannesson M; Hedbrant J; Jönsson B
    Med Inform (Lond); 1991; 16(4):355-62. PubMed ID: 1762471
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Results of a Markov model analysis to assess the cost-effectiveness of statin therapy for the primary prevention of cardiovascular disease in Korea: the Korean Individual-Microsimulation Model for Cardiovascular Health Interventions.
    Kang HY; Ko SK; Liew D
    Clin Ther; 2009 Dec; 31(12):2919-30; discussion 2916-8. PubMed ID: 20110032
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validation of a Cardiovascular Disease Policy Microsimulation Model Using Both Survival and Receiver Operating Characteristic Curves.
    Pandya A; Sy S; Cho S; Alam S; Weinstein MC; Gaziano TA
    Med Decis Making; 2017 Oct; 37(7):802-814. PubMed ID: 28490271
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A review of cost-effectiveness analyses.
    Hurley S
    Med J Aust; 1990 Aug; 153(S1):S20-3. PubMed ID: 2116583
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predicting the impact of population level risk reduction in cardio-vascular disease and stroke on acute hospital admission rates over a 5 year period--a pilot study.
    Whitfield MD; Gillett M; Holmes M; Ogden E
    Public Health; 2006 Dec; 120(12):1140-8. PubMed ID: 17084425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term health outcomes and cost-effectiveness of a computer-tailored physical activity intervention among people aged over fifty: modelling the results of a randomized controlled trial.
    Peels DA; Hoogenveen RR; Feenstra TL; Golsteijn RH; Bolman C; Mudde AN; Wendel-Vos GC; de Vries H; Lechner L
    BMC Public Health; 2014 Oct; 14():1099. PubMed ID: 25342517
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Markov model of the cost-effectiveness of pharmacist care for diabetes in prevention of cardiovascular diseases: evidence from Kaiser Permanente Northern California.
    Yu J; Shah BM; Ip EJ; Chan J
    J Manag Care Pharm; 2013 Mar; 19(2):102-14. PubMed ID: 23461426
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A model for evaluating the cost-effectiveness of cholesterol-lowering treatment.
    Glick H; Heyse JF; Thompson D; Epstein RS; Smith ME; Oster G
    Int J Technol Assess Health Care; 1992; 8(4):719-34. PubMed ID: 1464491
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of clopidogrel plus aspirin versus aspirin alone for secondary prevention of cardiovascular events: results from the CHARISMA trial.
    Chen J; Bhatt DL; Dunn ES; Shi C; Caro JJ; Mahoney EM; Gabriel S; Jackson JD; Topol EJ; Cohen DJ
    Value Health; 2009 Sep; 12(6):872-9. PubMed ID: 19490556
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How cost-effective are new preventive strategies for cardiovascular disease?
    Probstfield JL
    Am J Cardiol; 2003 May; 91(10A):22G-27G. PubMed ID: 12781905
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Health and Economic Implications of National Treatment Coverage for Cardiovascular Disease in India: Cost-Effectiveness Analysis.
    Basu S; Bendavid E; Sood N
    Circ Cardiovasc Qual Outcomes; 2015 Nov; 8(6):541-51. PubMed ID: 26555122
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness analysis of hypertension treatment--a review of methodological issues.
    Johannesson M; Jönsson B
    Health Policy; 1991 Sep; 19(1):55-77. PubMed ID: 10117392
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Resource implications and health benefits of primary prevention strategies for cardiovascular disease in people aged 30 to 74: mathematical modelling study.
    Marshall T; Rouse A
    BMJ; 2002 Jul; 325(7357):197. PubMed ID: 12142309
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness analysis with defined budget: how to distribute resources for the prevention of cardiovascular disease?
    Lindholm L; Hallgren CG; Boman K; Markgren K; Weinehall L; Ogren JE
    Health Policy; 1999 Sep; 48(3):155-70. PubMed ID: 11067036
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The cost-effectiveness of HMG-CoA reductase inhibitors to prevent coronary heart disease. Estimating the benefits of increasing HDL-C.
    Hamilton VH; Racicot FE; Zowall H; Coupal L; Grover SA
    JAMA; 1995 Apr; 273(13):1032-8. PubMed ID: 7897787
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dietary salt reduction and cardiovascular disease.
    Nair M; Prabhakaran D
    Natl Med J India; 2010; 23(6):352-3. PubMed ID: 21561048
    [No Abstract]   [Full Text] [Related]  

  • 17. A model for undertaking effectiveness and cost-effectiveness analyses of primary preventive strategies in cardiovascular disease.
    Liew D; Lim SS; Bertram M; McNeil JJ; Vos T
    Eur J Cardiovasc Prev Rehabil; 2006 Aug; 13(4):515-22. PubMed ID: 16874139
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Analysis of cost-effectiveness of simvastatin versus atorvastatin in the secondary prevention of cardiovascular events within the Brazilian public healthcare system].
    Araujo DV; Ribeiro de Souza CP; Bahia LR; Rey HC; Dos Santos Junior B; Tura BR; Berwanger O; Buehler AM; Silva MT
    Value Health; 2011; 14(5 Suppl 1):S29-32. PubMed ID: 21839894
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of medical primary prevention strategies to reduce absolute risk of cardiovascular disease in Tanzania: a Markov modelling study.
    Ngalesoni FN; Ruhago GM; Mori AT; Robberstad B; Norheim OF
    BMC Health Serv Res; 2016 May; 16():185. PubMed ID: 27184802
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost effectiveness of ramipril in patients at high risk for cardiovascular events : economic evaluation of the HOPE (Heart Outcomes Prevention Evaluation) study for Germany from the Statutory Health Insurance perspective.
    Schädlich PK; Brecht JG; Rangoonwala B; Huppertz E
    Pharmacoeconomics; 2004; 22(15):955-73. PubMed ID: 15449961
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.